CMS Issues 2020 Hospital OPPS and ASC Payment System Final Rule

Holland & Knight LLP
Contact

Holland & Knight LLP

The Centers for Medicare & Medicaid Services (CMS) on Nov. 1, 2019, released the Calendar Year (CY) 2020 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule.

Among notable changes, CMS will continue payment reductions to hospitals purchasing 340B drugs and reduce payment for visits in excepted off-campus, provider-based departments (PBDs). There are also significant changes to the physician supervision requirement for hospital outpatient therapeutic services.

Also of note, CMS has opted to publish a separate final rule on price transparency. The rule appears to have been received by the White House Office of Management and Budget (OMB) on Oct. 29, 2019, and is pending review. According to The Wall Street Journal, the Trump Administration is delaying the price transparency rule because officials said they are working on expanding the plan to include insurers.

To learn more about the Hospital OPPS and ASC Payment System Final Rule, review the following resources:

Provisions of the Final Rule will go into effect on Jan. 1, 2020.

Below is a summary of highlights of the Final Rule.

HOPD and ASC Payment Updates

CMS is finalizing a 2.6 percent increase in the OPPS and ASC payment systems. Hospital outpatient departments (HOPDs) and ASCs failing to meet quality-reporting requirements will continue to receive a 2.0 percent reduction in payments for services. CMS estimates that total payments to OPPS and ASC providers (including beneficiary cost-sharing and estimated changes in enrollment, utilization and case-mix) for CY 2020 will be approximately $79 billion and $4.96 billion, respectively. This represents an increase of approximately $6.3 billion and $230 million, respectively, from CY 2019 payment levels.

Rural Adjustment

CMS will continue the 7.1 percent adjustment for OPPS payments to certain rural sole community hospitals (SCHs), including essential access community hospitals (EACHs). The adjustment would apply to all services paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, items paid at charges reduced to costs, and devices paid under the pass-through payment policy.

Payment Adjustment for Certain Cancer Hospitals

CMS will continue to provide additional payments to cancer hospitals so that the cancer hospital's payment-to-cost ratio (PCR) after the additional payments is equal to the weighted average PCR for other OPPS hospitals using the most recently submitted or settled cost report data. Beginning in CY 2018, Section 16002(b) of the 21st Century Cures Act requires that the weighted average PCR be reduced by 1.0 percentage point.

In the proposed rule, CMS set a target of 0.89 to determine the CY 2020 cancer hospital payment adjustment to be paid at cost report settlement. The payment adjustment would be the additional payments needed to result in a PCR equal to 0.89 for each cancer hospital.

CMS noted that it did not receive any public comments on the proposal. Therefore, it finalized the cancer hospital payment adjustment methodology without modification. CMS is using the most recent cost report data through June 30, 2019, to update the adjustment. The estimated 2020 hospital-specific payment adjustment for cancer hospitals may be found in Table 7 of the Final Rule.

Partial Hospitalization Program (PHP) Rate Setting

CMS will update Medicare payment rates for the Partial Hospitalization Program (PHP) services furnished in hospital outpatient departments and Community Mental Health Centers (CMHCs). The PHPs are structured intensive outpatient programs consisting of a group of mental health services paid on a per diem basis under the OPPS, based on PHP per diem costs.

Increasing Price Transparency of Hospital Standard Charges

In July, CMS proposed to implement the Executive Order on Improving Price and Quality Transparency and further implement Section 2718(e) of the Public Health Service Act requiring that U.S. hospitals annually make public a list of standard charges for items and services, via:

  • defining "hospital," "standard charges," and "items and services"
  • requirements for making public a machine-readable file online that includes all standard charges for all hospital items and services
  • requirements for making public payer-specific negotiated charges for a limited set of "shoppable" services that are displayed and packaged in a consumer-friendly manner
  • monitoring for hospital noncompliance and actions to address hospital noncompliance (including issuing a warning notice, requesting a corrective action plan and imposing civil monetary penalties), and a process for hospitals to appeal these penalties

CMS did not address this proposal in the Final Rule and instead plans to summarize and respond to the more than 1,500 public comments on the proposed policies in a separate forthcoming Final Rule. The rule reportedly is pending review by the White House OMB.

Payment for 340B Drugs and Biologics

For CY 2020, CMS will continue to pay ASP-22.5 percent for 340B-acquired drugs, including when furnished in nonexcepted off-campus PBDs paid under the Medicare Physician Fee Schedule (MPFS). Critical access hospitals, rural sole community hospitals, children's hospitals and PPS-exempt cancer hospitals remain excepted from the payment reduction. Hospitals subject to the payment reduction must continue to use claim-level modifiers "JG" and "TB" to signify when 340B and non-340B drugs are used, respectively.

The policy is currently subject to a lawsuit, which CMS is currently appealing to the U.S. Court of Appeals for the District of Columbia Circuit. The agency plans to survey hospitals on actual acquisition costs for 340B drugs shortly; a Paperwork Reduction Act (PRA) notice on the survey was released in September.

Thus, CMS will continue to apply the ASP-22.5 percent reduction until the D.C. Circuit's decision. The D.C. Circuit heard oral arguments in the ongoing litigation concerning the payment reductions for 340B drugs on Nov. 8, 2019. If affirmed, CMS will rely on pending 340B acquisition cost survey activity to establish an alternative to ASP-22.5 percent or use another option such as ASP+3 percent, which was discussed in the proposed rule.

Site-Neutral Payments for Hospital Clinic Visits

As finalized in the CY 2019 OPPS/ASC final rule, CMS will complete implementation of the two-year phase-in of applying the MPFS rate for the clinic visit service (G0463: Hospital Outpatient Clinic Visit for Assessment and Management of a Patient) when provided at an off-campus PBD and reimbursed under OPPS. This clinic visit is the most common service billed under OPPS and typically occurs in the physician's office. CMS instituted the proposal based on its authority to restrict unnecessary increases in the volume of covered services.

Notably, the U.S. District Court for the District of Columbia on Sept. 17, 2019, issued a decision against the CMS "site-neutral" payment policy that was included in the CY 2019 OPPS rule. In this Final Rule, CMS acknowledged the District Court's decision and said that it is still evaluating the rulings and considering whether to appeal the final judgment.

Proposed Prior Authorization Process and Requirements for Certain HOPD Services

CMS finalized its proposal to require prior authorization for the following five services to ensure they are billed only when medically necessary: 1) blepharoplasty, 2) botulinum toxin injections, 3) panniculectomy, 4) rhinoplasty and 5) vein ablation. CMS reviewed claims data and identified these services as demonstrating an unnecessary increase in volume.

CMS may elect to exempt a provider from the prior authorization process upon a provider's demonstration of compliance with Medicare coverage, coding and payment rules. The exemption would remain in effect until CMS elects to withdraw it. CMS will exempt providers that achieve a prior authorization provisional affirmation threshold of at least 90 percent during a semiannual assessment

Wage Index Policy

CMS will continue its policy to use the wage index policies and adjustments proposed in the Inpatient Prospective Payment System (IPPS) for non-IPPS facilities paid under the OPPS. This update will result in an estimated payment increase of 0.7 percent for rural hospitals and no changes in payment for urban hospitals.

For the Fiscal Year (FY) 2020 IPPS wage index, CMS finalized adjustments to address what it sees as the disparity between urban and rural hospitals. Hospitals in the bottom 25th percentile of the wage index will receive a boost of 50 percent of the difference between current applicable wage index value for the hospital and the 25th percentile wage index value for all hospitals. The agency initially proposed to offset this higher spending by decreasing the wage index for hospitals in the 75th percentile or higher. However, responding to concerns of commenters, CMS instead finalized a budget neutrality adjustment by reducing payment across the board. Cuts will be capped at a maximum of 5 percent decrease from a hospital's FY 2019 wage index. In addition, the removal of urban to rural hospital reclassifications from the calculation of the rural floor wage index that was finalized in the FY 2020 IPPS rule is also reflected in this Final Rule.

Changes to the Inpatient-Only List

CMS will remove total hip arthroplasty from the Inpatient-Only (IPO) list, making it eligible to be paid by Medicare in both the hospital inpatient and outpatient settings. Additionally, six spinal procedure codes and five anesthesia codes are removed from the IPO list for CY 2020.

To comply with the two-midnight rule and to avoid unnecessary Recovery Audit Contractor (RAC) audits for procedures that are removed from the IPO list for CY 2020 and subsequent years, CMS finalized a two-year exemption from medical review activities pertaining to patient status. CMS had initially proposed only a one-year exemption.

Under the current two-midnight policy for evaluating short hospital inpatient stays, when the procedure performed appears on CMS' IPO list, the entire claim is exempt from medical review under the two-midnight benchmark regardless of the actual or expected length of stay. But when a procedure is removed from the IPO list, the two-midnight benchmark applies, and the claims historically have been subject to initial medical reviews by Beneficiary and Family Centered Care-Quality Improvement Organizations (BFCC-QIOs), who can also refer providers to RACs.

Hospital Outpatient and ASC Quality Reporting Programs

For the CY 2020 Hospital Outpatient Quality Reporting (OQR) Program, CMS will remove OP-33: External Beam Radiotherapy for Bone Metastases for the CY 2022 payment determination and subsequent years with modification.

For the ASC Quality Reporting (ASCQR) Program, CMS will adopt one new measure, ASC-19: Facility-Level 7-Day Hospital Visits after General Surgery Procedures Performed at Ambulatory Surgical Centers, beginning with the CY 2024 payment determination and for subsequent years.

Comprehensive Ambulatory Payment Classifications (APCs)

CMS created two new comprehensive APCs (C-APCs): C-APC 5182 (Level 2 Vascular Procedures) and C-APC 5461 (Level 1 Neurostimulator and Related Procedures). This increases the total number of C-APCs to 67.

Additional Drugs Receive Pass-Through in 2020 and New Breakthrough Device Pathway

A total of 80 drugs and biologics will have pass-through status in 2020. Of these, three are new injectables effective on Jan. 1, 2020: lefamulin, brexanolone, polatuzumab.

Seven applications for device pass-through payment were received. Also, there will be a new additional pathway for devices to qualify for pass-through status; devices would not need to meet the substantial clinical improvement criterion, but would still need to meet the other criteria. Two applications were approved for pass-through status under the breakthrough device alternative pathway. They are the Optimizer(r) Smart System and the CustomFlex(r) Artificial Iris.

Changes to the Level of Supervision of Outpatient Therapeutic Services in Hospitals and Critical Access Hospitals

For CY 2020, CMS will change the minimum required level of supervision from direct supervision to general supervision for all hospital outpatient therapeutic services.This change applies to all hospitals, including critical access hospitals (CAHs) and small rural hospitals, for which CMS reinstated the non-enforcement policy for direct supervision of outpatient therapeutic services for CY 2018 and 2019 in the 2018 Hospital OPPS final rule.

Two-Year Transition of CT and MRI Cost-to-Charge Ratios (CCRs)

CMS is finalizing a two-year phased-in approach that will apply 50 percent of the payment impact from ending the transition in CY 2020 and 100 percent of the payment impact from ending the transition in CY 2021. For CY 2020, CMS will calculate the imaging payment rates using both the transition methodology (excluding providers that use a "square feet" cost allocation method) and the standard methodology (including all providers, regardless of cost allocation method), and will assign the imaging APCs a payment rate that includes data representing 50 percent of the transition methodology payment rate and includes data representing 50 percent of the standard methodology payment rate.

Table 4 in the Final Rule illustrates the estimated impact on geometric mean costs for CT and MRI APCs under the blended approach of utilizing 50 percent of the transitional payment methodology and 50 percent of the standard payment methodology for CY 2020.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Holland & Knight LLP | Attorney Advertising

Written by:

Holland & Knight LLP
Contact
more
less

Holland & Knight LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.